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‘Post-operative chemotherapy cannot be considered as a standard
adjuvant treatment for gastric cancer.’ This was the conclusion of a
meta-analysis in 1993 of 11 trials including 2096 patients in which
post-operative adjuvant chemotherapy was compared to surgery
alone (Hermans et al, 1993). The authors found a non-significant
survival advantage (odds-ratio (OR) 0.88, 95% confidence interval
(CI) 0.78–1.08). However, this figure was later adjusted to include
data from studies omitted in error to a statistically significant
result (OR 0.82, 95% CI: 0.68–0.97) (Hermans and Bonenkamp,
1994). 
A more recent meta-analysis evaluated 13 randomized con-
trolled trials performed between 1966–99 (Earle and Maroun,
1999). All of the studies had a surgery-alone control arm versus
post-operative chemotherapy of varying regimens in non-Asian
patients. The overall crude odds-ratio for death in the treated group
(preserving stratification by study, but not adjusting for prognostic
variables) was 0.80 (95% CI: 0.66–0.97). The magnitude of the
effect was smaller for trials with more than 5 years follow-up
although a trend towards benefit was maintained suggesting a
long-term effect, not just delaying relapse. In addition, this effect
was most marked in lymph node-positive disease by sub-group
analysis. 
Since this meta-analysis 3 further studies have been reported
suggesting a benefit from adjuvant chemotherapy or chemo-
radiotherapy after surgery for gastric cancer. Cirera et al (1999)
randomized 156 patients who had undergone resection of stage III
disease to receive either no further treatment (control arm) or
chemotherapy comprised of a single dose of mitomycin-C (20 mg/
m2 on day 1) followed by oral tegafur (400 mg bd, starting on day
30 and continued for 3 months). After a median follow-up of 37
months, there was a significant difference in overall survival
(median survival 74 vs. 29 months, P = 0.04) and disease-free
survival (63 vs. 22 months, P = 0.01) favouring the chemotherapy-
arm. The 2-year and 5-year survival figures were 72% vs. 58% and
56% vs. 36%, respectively, also in favour of the chemotherapy-
arm. The estimated hazard ratio for mortality in the treatment
group compared to the control arm was 0.60 (95% CI: 0.39–0.93). 
Neri et al (2001) in this edition, publish an update of their previ-
ously presented study (Neri et al, 1996). This update provides 5-
year follow-up data (previously an interim analysis after 36
months) on 137 patients. All patients had lymph node-positive
disease and were randomized to either surgery alone or surgery
followed by chemotherapy with epidoxorubicin 75 mg/m2 (day 1)
and leucovorin 200 mg/m2 plus 5-FU 450 mg/m2 (days 1–3),
repeated every 3 weeks for 7 months. 88% of patients randomized
to receive chemotherapy received all planned cycles of treatment.
The median survival of patients having surgery alone was 
18 months compared to 31 months in the chemotherapy group 
(P < 0.01), with an estimated hazard ratio for mortality of 1.96 for
the control arm compared to the chemotherapy-arm (95% CI:
1.32–2.92). 
The results of Intergroup Study INT-0116 were presented at the
American Society of Clinical Oncology annual meeting this year
(Macdonald et al, 2000). In this large study, 603 patients were
randomized to either surgery alone or surgery followed by
adjuvant chemo-radiotherapy. This consisted of one cycle of
leucovorin/5-FU (20 mg/m2 and 425 mg/m2, days 1–5) followed by
4500 cGy in 25 fractions given with leucovorin/5-FU (20 mg/m2
and 400 mg/m2) on days 1–4 and 23–25 of radiotherapy. This was
followed, a month later, by 2 further cycles of leucovorin/5-FU
(20 mg/m2 and 425 mg/m2, days 1–5, given at monthly intervals).
After a median follow-up of 3.3 years, there was a significantly
improved overall survival (3-year survival: 52% vs. 41%, 
P = 0.03) and disease-free survival (3-year DFS: 49% vs. 32%, 
P = 0.001), both in favour of the chemo-radiotherapy arm. The
median survival was 27 months in the surgery alone arm vs. 42
months in the combined modality arm (estimated mortality hazard
ratio of 1.28). 
Are we to conclude, therefore, that adjuvant treatment is now
the standard of care in gastric cancer? The patient population
assessed in the 3 studies outlined above is not uniform. In the
Spanish study (Cirera et al, 1999) all patients had stage III disease,
which would have included node-negative patients (see Table 1).
Only 7% of control patients compared to 20% of chemotherapy
patients had N0 disease. However, these differences did not reach
statistical significance (P = 0.07) and the beneficial effects of
chemotherapy remained after adjustment for nodal infiltration.
Neri et al selected node-positive patients only and the numbers of
patients with N1 and N2 disease was balanced between the control
and chemotherapy arms. However, patients with lymph node-
positive disease can range from stage IB (T1N1M0) to stage IV
(T4, N2–3) according to AJCC criteria (AJCC, 1997). The intergroup
Study, INT-0116, randomized patients with stages IB through to
IV, including patients with both lymph node-positive and -negative
disease. 85% of patients had nodal metastases and the distribution
of N0 disease was balanced with 16% in the surgery-alone arm
and 14% in the chemotherapy arm. There were too few patients
(n = 36, 18 in each arm) in the stage IB sub-group to make any
firm conclusions about these patients who, even without treatment
have a relatively good prognosis. 
The extent of surgery was also different in the 3 studies. Cirera
et al recruited patients who had surgical margins free from tumour
and who had undergone an extended lymphadenectomy (R2 resec-
tion). This may account for their excellent 5-year survival figures
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follow-up is relatively short (37 months) and mature data is
awaited. In the Italian study (Neri et al, 2000) 13% of patients in
the control arm and 15% of patients in the chemotherapy arm
underwent an R2 resection, the remainder undergoing either R1A
or R1B resections. However, in their multivariate analysis, the
type of surgery was not found to be a significant prognostic factor
(P > 0.75). 
Is this finding significant? Two surgical studies in which a total
of 989 patients who had undergone a R0 resection and were then
randomized to either a D1 or D2 lymph node dissection have
failed to show a survival benefit from extended lymph node
dissection at 3 years. In the first, the 3-year survival was 56% (D1
resection) vs. 58% (D2 resection) among 589 patients randomized
in the Dutch Gastric Cancer Trial (Bonenkamp et al, 1999). The
Medical Research Council, in the second study showed a 50% vs.
57% 3-year survival (D1 vs. D2 respectively) among 400 patients
(Cuschieri et al, 1999). It must be noted that surgical morbidity
and mortality were higher for the D2-treated patients. In the INT-
0116 study, 10% of patients had a D2 resection, 36% a D1 resec-
tion and 54% did not conform to a D1 resection (<D1). However,
in the chemo-radiotherapy arm the 3-year survival was 52%,
approximating the 3-year survival following D1 resection in the 2
surgical studies raising the possibility that chemo-radiotherapy is
making up for sub-optimal surgery. This adds weight to the view
that surgery for gastric cancer should be performed by experienced
surgeons aiming for a D1 resection. Further studies assessing the
value of chemotherapy or chemo-radiotherapy in patients who
undergo adequate surgery are warranted given the positive find-
ings of Neri et al and Cirera et al. 
In the Spanish study (Cirera et al, 1999) the most frequent sites
of relapse occurred at local and peritoneal sites (48% controls vs.
54% treatment group). Patients in the INT-0116 study had a
reduced local relapse rate in the treatment arm (19% vs. 29%
controls) and a higher distant relapse rate (35% vs. 18% controls).
Is the role of radiotherapy, therefore, to complement surgery when
resection has been sub-optimal, and would this benefit be lost if all
patients underwent at least a D1 resection? This will only be made
clear by future studies. Unfortunately, Neri et al do not provide
data for sites of relapse. 
At what price to the patient is this survival benefit being
achieved? The mitomycin-C and tegafur combination was particu-
larly well tolerated with only one documented grade III toxicity
(neurocerebellar). Grade II toxicity included nausea and vomiting
(n = 5) and leucopenia (n = 1), mucositis (n = 1) and diarrhoea 
(n = 1). The epidoxorubicin, leucovorin and 5-FU combination
was more toxic with grade III/IV toxicity as follows: mucositis
(12%), diarrhoea (8.7%), leucopenia (8.7%), anaemia (4.3%) and
thrombocytopenia (2.9%). Despite this, no patients required hospi-
talization. Chemo-radiotherapy was described as tolerable but was
much more toxic with grade III toxicity in 41% overall (haemato-
logical 54%, gastro-intestinal 33%, infection 6% and neurological
4%) and grade IV toxicity in 32% of cases. There were 3 (1%)
toxic deaths. In order to minimize the toxicity of this regimen, all
radiotherapy fields were reviewed and, following this review,
radiotherapy planning was changed in 34% of cases. It is estimated
that had this review not been performed, serious, potentially life-
threatening toxicity may have occurred in up to 10% of cases
(Kelsen, 2000). 
It seems that the body of evidence is changing since the conclu-
sion of the 1993 meta-analysis. Several positive studies advocate
the use of adjuvant chemotherapy or chemo-radiotherapy. Patients
with lymph node-positive disease appear to benefit (although
evidence is lacking for patients with stage IB disease) as do
patients with stage III disease (whether lymph node-positive or 
-negative). Improving the numbers of patients who undergo a D1-
lymph node resection may improve overall survival and may also
negate the need for the radiotherapy modality in chemo-
radiotherapy. Given the heterogeneity of the regimens used in
these studies, the optimum regimen for use has still not been
defined. Additionally, the effect of other approaches such as
neo-adjuvant chemotherapy or chemo-radiotherapy and the role
of newer generation cytotoxic agents (such as docetaxel and
irinotecan, either alone or in combination with current agents) has
yet to be determined. This group of patients should continue to be
encouraged to participate in well-designed randomized controlled
trials, some of which are already underway. 
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Table 1 AJCC group staging for gastric cancer 
Group staging 
Stage 0 Tis N0 M0 
Stage IA T1 N0 M0 
Stage IB T1 N1 M0 
T2 N0 M0 
Stage II T1 N2 M0 
T2 N1 M0 
T3 N0 M0 
Stage IIIA T2 N2 M0 
T3 N1 M0 
T4 N0 M0 
Stage IIIB T3 N2 M0 
Stage IV T4 N1 M0 
T1 N3 M0 
T2 N3 M0 
T3 N3 M0 
T4 N2 M0 
T4 N3 M0 
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